Showing results (731-740 of 784) with videos related to
Sort By:
Pageof 79
The New England Journal of Medicine|January 13, 2012
Germline mutations in HOXB13 and prostate-cancer riskCharles M Ewing, Anna M Ray, Ethan M Lange, et al.Cancer Research|March 1, 2005
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer riskGoutham Narla, Analisa Difeo, Helen L Reeves, et al.The Lancet. Rheumatology|January 23, 2026
Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trialAndrew P Cope, Marianna Jasenecova, Joana C Vasconcelos, et al.Arthritis Research & Therapy|January 12, 2005
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopeniaFrederique Ponchel, Robert J Verburg, Sarah J Bingham, et al.Age and Ageing|November 16, 2020
Mild cognitive impairment: the Manchester consensusRoss A Dunne, Dag Aarsland, John T O'Brien, et al.Annals of the Rheumatic Diseases|February 24, 2022
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 updateRobert B M Landewé, Féline P B Kroon, Alessia Alunno, et al.Journal of the National Cancer Institute|December 13, 2007
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IPDavid Duggan, Siqun L Zheng, Michele Knowlton, et al.Journal of the National Cancer Institute|August 19, 2004
Combined genome-wide scan for prostate cancer susceptibility genesElizabeth M Gillanders, Jianfeng Xu, Bao-li Chang, et al.Nature Reviews. Rheumatology|July 14, 2017
Synovial tissue research: a state-of-the-art reviewCarl Orr, Elsa Vieira-Sousa, David L Boyle, et al.Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.Pageof 79